Amgen vs. Merck: Dividend Investors Weigh Pipeline Risk Against Yield Stability

The Quick Take

• Amgen and Merck offer comparable dividend yields for income-focused investors in the healthcare sector.
• Both companies face patent expirations and pricing headwinds that could pressure long-term payout sustainability.
• Pipeline strength and drug pricing reform outcomes remain the key differentiating factors.

A comparative analysis of Amgen and Merck highlights the trade-offs facing income investors seeking exposure to large-cap pharmaceutical names. Both companies offer dividend yields in the three-to-four percent range, providing a meaningful premium over the broader S&P 500 average. However, each faces distinct challenges to long-term earnings sustainability. Amgen confronts significant patent expirations on several blockbuster biologics, while Merck depends heavily on Keytruda, whose revenue profile faces constraints as the Inflation Reduction Act's drug pricing negotiation framework expands into additional therapeutic categories.

Dividend growth track records offer one lens for comparison. Amgen has raised its dividend consistently over more than a decade, supported by strong free cash flow from its established biologics portfolio and cost-efficient manufacturing base. Merck, similarly, has maintained an uninterrupted dividend payment history with periodic increases. Both companies are investing heavily in next-generation pipelines including ADC therapies, obesity drugs, and gene editing platforms, which requires substantial R&D capital that could constrain dividend growth acceleration in the medium term.

For income investors assessing the two names, Merck's somewhat higher yield reflects a market discount tied to pipeline concentration risk around Keytruda's post-2028 exclusivity cliff. Amgen's diversified biologics portfolio and biosimilars expansion provide a broader earnings base, though acquisition-related leverage adds financial risk. Analysts suggest the choice ultimately depends on individual risk tolerance toward pipeline execution versus yield premium. Both remain core healthcare income holdings, but active monitoring of regulatory and clinical milestones is essential for maintaining conviction in either position.

Synthesized from 1 source.